Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats

International Journal of Cardiology

Volumn 97, Issue 3, 2004, Pages 373-381

  Gagnon, C ^a   Legault, F ^a   Geraldes, P ^b   Tanguay, J F ^b   Lambert, C ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

Author keywords

ACE inhibitors; Angiotensin; Collagen; Fibrosis; Hypertension; Hypertrophy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PREVENTION; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; COLLAGEN; HEART RATE; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ANGIOTENSIN; TISSUE DISTRIBUTION;

EID: 9244255292     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.10.016     Document Type: Article

References (53)

1. Kannel W.B., Levy D., Cupples L.A. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J. Cardiovasc. Pharmacol. 10(Suppl. 6):1987;S135-S140
2. Brilla C.G., Reams G.P., Maisch B., et al. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur. Heart J. 14(Suppl. J):1993;57-61
3. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 102:2000;1388-1393
4. Nishimura H., Kubota J., Okabe M., et al. Effects of lisinopril upon cardiac hypertrophy, central and peripheral hemodynamics and neurohumoral factors in spontaneously hypertensive rats. J. Hypertens. 10:1992;431-436
5. Brilla C.G. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc. Res. 47:2000;1-3
6. Bishop J.E., Kiernan L.A., Montgomery H.E., et al. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. Cardiovasc. Res. 47:2000;57-67
7. Brilla C.G., Zhou G., Matsubara L., et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol. 26:1994;809-820
8. Weber K.T. Targeting pathological remodeling: concepts of cardioprotection and reparation. Circulation. 102:2000;1342-1345
9. Brilla C.G. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc. Res. 46:2000;324-331
10. Mitchell G.F., Pfeffer J.M., Pfeffer M.A. The transition to failure in the spontaneously hypertensive rat. Am. J. Hypertens. 10:1997;120S-126S
11. Sen S., Tarazi R.C., Bumpus F.M. Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension. 2:1980;169-176
12. White C.M. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 18:1998;588-599
13. Cushman D.W., Wang F.L., Fung W.C., et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 28(Suppl. 2):1989;115S-130S
14. Fortuno M.A., Ravassa S., Etayo J.C., et al. Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan. Hypertension. 32:1998;280-286
15. Varo N., Etayo J.C., Zalba G., et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J. Hypertens. 17:1999;107-114
16. Wagner J., Drab M., Bohlender J., et al. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin. Exp. Hypertens. 20:1998;205-221
17. Tsoporis J., Fields N., Lee R.M., et al. Arterial vasodilation and cardiovascular structural changes in normotensive rats. Am. J. Physiol. 260:1991;H1944-H1952
18. Mukherjee D., Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ. Res. 67:1990;1474-1480
19. Yang C.M., Kandaswamy V., Young D., et al. Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc. Res. 36:1997;236-245
20. Mukherjee D., Sen S. Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure. J. Mol. Cell. Cardiol. 25:1993;185-196
21. Jalil J.E., Doering C.W., Janicki J.S., et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res. 64:1989;1041-1050
22. Harrap S.B., Nicolaci J.A., Doyle A.E. Persistent effects on blood pressure and renal haemodynamics following chronic angiotensin converting enzyme inhibition with perindopril. Clin. Exp. Pharmacol. Physiol. 13:1986;753-765
23. Kost C.K. Jr., Rominski B.R., Herzer W.A., et al. Persistent improvement of cardiovascular risk factors in spontaneously hypertensive rats following early short-term captopril treatment. Clin. Exp. Hypertens. 22:2000;127-143
24. Swislocki A.L., LaPier T.L., Khuu D.T., et al. Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. Am. J. Hypertens. 12:1999;581-589
25. Yonezawa T., Umemoto S., Fujii A., et al. Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 27:1996;119-124
26. Susic D., Varagic J., Frohlich E.D. Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J. Hypertens. 17:1999;1209-1215
27. Zhu Y.C., Zhu Y.Z., Gohlke P., et al. Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am. J. Cardiol. 80:1997;110A-117A
28. Bastien N.R., Juneau A.V., Ouellette J., et al. Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival. Cardiovasc. Res. 43:1999;77-85
29. Harrap S.B., Van der Merwe W.M., Griffin S.A., et al. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension. 16:1990;603-614
30. Clozel J.P., Kuhn H., Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J. Hypertens. 7:1989;267-275
31. Linz W., Wiemer G., Schaper J., et al. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol. Cell. Biochem. 147:1995;89-97
32. Mori T., Nishimura H., Ueyama M., et al. Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats. Jpn. Circ. J. 59:1995;624-630
33. Brilla C.G., Janicki J.S., Weber K.T. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ. Res. 69:1991;107-115
34. Weber KT, Janicki JS, Shroff SG. The mechanics of ventricular function. Hosp Pract (Off Ed) 1983;18:113-7, 121-5.
35. Varo N., Iraburu M.J., Varela M., et al. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 35:2000;1197-1202
36. Brilla C.G., Matsubara L., Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension. 28:1996;269-275
37. Chevalier B., Heudes D., Heymes C., et al. Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation. 92:1995;1947-1953
38. Kojima M., Shiojima I., Yamazaki T., et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 89:1994;2204-2211
39. Yamamoto K., Masuyama T., Sakata Y., et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc. Res. 55:2002;76-82
40. Pathak M., Sarkar S., Vellaichamy E., et al. Role of myocytes in myocardial collagen production. Hypertension. 37:2001;833-840
41. Panizo A., Pardo J., Hernandez M., et al. Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. Am. J. Hypertens. 8:1995;815-822
42. Sia Y.T., Lapointe N., Paker T.G., et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation. 105:2002;2549-2555
43. Palace V.P., Hill M.F., Farahmand F., et al. Mobilization of antioxidant vitamin pools and hemodynamic function after myocardial infarction. Circulation. 99:1999;121-126
44. Kinaguwa S., Tsutsui H., Hayashidani S., et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice. Circ. Res. 87:2000;392-398
45. Sia Y.T., Parker T.G., Liu P., et al. Improved post-myocardial infarction survival with probucol in rats: effects on left ventricular function, morphology, cardiac oxidative stress and cytokine expression. J. Am. Coll. Cardiol. 39:2002;148-156
46. Chopra M., McMurray J., Stewart J., et al. Free radical scavenging: a potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors. Biochem. Soc. Trans. 18:1990;1184-1185
47. Cominacini L., Fratta A., Pasini U., et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 15:2002;891-895
48. Buikema H., Monnink S.H., Tio R.A., et al. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br. J. Pharmacol. 130:2000;1999-2007
49. De Nigris F., D'Armiento F.P., Somma P., et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int. J. Cardiol. 81:2001;107-115
50. Sacco G., Bigioni M., Evangelista S., et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur. J. Pharmacol. 414:2001;71-78
51. Subissi A., Evangelista S., Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 17:1999;115-133
52. Ambrosioni E., Borghi C. Magnani B for the Survival of Myocardial Infarction Long-Term Evaluation Study (SMILE study) Investigators. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N. Engl. J. Med. 332:1995;80-85
53. Borghi C., Ambrosioni E. Magnani B on behalf of SMILE study Investigators. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. Am. J. Cardiol. 78:1996;317-322